128 related articles for article (PubMed ID: 30156339)
1. Concise Review: Cheating Death for a Better Transplant.
Afreen S; Weiss JM; Strahm B; Erlacher M
Stem Cells; 2018 Nov; 36(11):1646-1654. PubMed ID: 30156339
[TBL] [Abstract][Full Text] [Related]
2. Transient apoptosis inhibition in donor stem cells improves hematopoietic stem cell transplantation.
Kollek M; Voigt G; Molnar C; Murad F; Bertele D; Krombholz CF; Bohler S; Labi V; Schiller S; Kunze M; Geley S; Niemeyer CM; Garcia-Saez A; Erlacher M
J Exp Med; 2017 Oct; 214(10):2967-2983. PubMed ID: 28882984
[TBL] [Abstract][Full Text] [Related]
3. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
4. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
5. Rapid hematopoietic engraftment following fractionated TBI conditioning and transplantation with CD34(+) enriched hematopoietic progenitor cells from partially mismatched related donors.
Redei I; Langston AA; Lonial S; Cherry JK; Allen AJ; Hamilton E; Jones M; Bartlett VM; Waller EK
Bone Marrow Transplant; 2002 Sep; 30(6):335-40. PubMed ID: 12235516
[TBL] [Abstract][Full Text] [Related]
6. Lentivirus-Mediated BCL-X
Zehnle PMA; Wu Y; Koleci N; Bohler S; Erlacher M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612914
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
9. Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders.
Slavin S; Nagler A; Aker M; Shapira MY; Cividalli G; Or R
Rev Clin Exp Hematol; 2001 Jun; 5(2):135-46. PubMed ID: 11486652
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
11. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
[TBL] [Abstract][Full Text] [Related]
12. Assessment of cell viability and apoptosis in human umbilical cord blood following storage.
Xiao M; Dooley DC
J Hematother Stem Cell Res; 2003 Feb; 12(1):115-22. PubMed ID: 12662442
[TBL] [Abstract][Full Text] [Related]
13. Graft failure after allogeneic hematopoietic stem cell transplantation.
Ozdemir ZN; Civriz Bozdağ S
Transfus Apher Sci; 2018 Apr; 57(2):163-167. PubMed ID: 29724627
[TBL] [Abstract][Full Text] [Related]
14. Caspase inhibitor ZVAD-fmk facilitates engraftment of donor hematopoietic stem cells in intra-bone marrow-bone marrow transplantation.
Imai Y; Adachi Y; Shi M; Shima C; Yanai S; Okigaki M; Yamashima T; Kaneko K; Ikehara S
Stem Cells Dev; 2010 Apr; 19(4):461-8. PubMed ID: 19686047
[TBL] [Abstract][Full Text] [Related]
15. Non-myeloablative transplants for malignant disease.
Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
[TBL] [Abstract][Full Text] [Related]
17. Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma.
Bhatt VR; Armitage JO
Expert Opin Biol Ther; 2016; 16(1):57-66. PubMed ID: 26515478
[TBL] [Abstract][Full Text] [Related]
18. Extensive early apoptosis in frozen-thawed CD34-positive stem cells decreases threshold doses for haematological recovery after autologous peripheral blood progenitor cell transplantation.
de Boer F; Dräger AM; Pinedo HM; Kessler FL; van der Wall E; Jonkhoff AR; van der Lelie J; Huijgens PC; Ossenkoppele GJ; Schuurhuis GJ
Bone Marrow Transplant; 2002 Feb; 29(3):249-55. PubMed ID: 11859398
[TBL] [Abstract][Full Text] [Related]
19. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease.
Dunbar EM; Buzzeo MP; Levine JB; Schold JD; Meier-Kriesche HU; Reddy V
Haematologica; 2008 Dec; 93(12):1852-8. PubMed ID: 18945751
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic Hematopoietic Stem Cell Transplantation in Thirty-Four Pediatric Cases of Mucopolysaccharidosis-A Ten-Year Report from the China Children Transplant Group.
Wang J; Luan Z; Jiang H; Fang J; Qin M; Lee V; Chen J
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2104-2108. PubMed ID: 27555533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
